Program
AK3280
A development code.
Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Shanghai Ark Biopharmaceutical.
Furthest: phase 3, since Jul 17, 20264 company-led studies, 1 open or runningNext primary completion: Sep 30, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Ark Biopharmaceutical | 41 open or running | phase 3since Jul 17, 2026 | Jun 12, 2019 | Sep 30, 2028phase 3 · NCT07719023 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 12, 2019First study: phase 1 study in HealthyFirst studyNCT03990688 · 48 enrolled · Sweden
- Jun 7, 2021Phase 1 study in HealthyNCT04926116 · 24 enrolled · China
- May 9, 2022Phase 2 study in Idiopathic Pulmonary FibrosisNCT05424887 · 105 enrolled · China
- Jul 17, 2026Phase 3 study in Idiopathic Pulmonary FibrosisPhase 3 reachedNCT07719023 · 263 planned · China
Ahead
- Sep 30, 2028Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT07719023
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07719023Idiopathic Pulmonary Fibrosis · China | 3 | Not yet recruiting | Sep 30, 2028 | 263 |
| NCT05424887Idiopathic Pulmonary Fibrosis · China | 2 | UNKNOWN | Jul 2024 | 105 |
| NCT04926116Healthy · China | 1 | Completed | Sep 28, 2021 | 24 |
| NCT03990688Healthy · Sweden | 1 | Completed | Sep 9, 2020 | 48 |
How it is read
Names in the registry
- “AK3280”, 4 entries
Codes read as this program: AK3280.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.